Exelixis, Inc. (EXEL)
54.57
+0.49
(+0.91%)
USD |
NASDAQ |
Aug 24, 16:00
54.57
0.00 (0.00%)
After-Hours: 20:00
Exelixis Enterprise Value : 12.79B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 12.79B |
| August 20, 2026 | 12.69B |
| August 19, 2026 | 12.86B |
| August 18, 2026 | 12.55B |
| August 17, 2026 | 12.35B |
| August 14, 2026 | 12.08B |
| August 13, 2026 | 11.92B |
| August 12, 2026 | 11.87B |
| August 11, 2026 | 12.10B |
| August 10, 2026 | 12.51B |
| August 07, 2026 | 12.78B |
| August 06, 2026 | 12.32B |
| August 05, 2026 | 13.44B |
| August 04, 2026 | 13.26B |
| August 03, 2026 | 13.03B |
| July 31, 2026 | 12.52B |
| July 30, 2026 | 13.26B |
| July 29, 2026 | 13.10B |
| July 28, 2026 | 13.39B |
| July 27, 2026 | 13.22B |
| July 24, 2026 | 13.11B |
| July 23, 2026 | 13.18B |
| July 22, 2026 | 13.01B |
| July 21, 2026 | 13.29B |
| July 20, 2026 | 13.15B |
| Date | Value |
|---|---|
| July 17, 2026 | 13.24B |
| July 16, 2026 | 13.18B |
| July 15, 2026 | 13.15B |
| July 14, 2026 | 13.21B |
| July 13, 2026 | 13.27B |
| July 10, 2026 | 13.39B |
| July 09, 2026 | 13.54B |
| July 08, 2026 | 13.29B |
| July 07, 2026 | 13.53B |
| July 06, 2026 | 13.15B |
| July 02, 2026 | 13.23B |
| July 01, 2026 | 12.76B |
| June 30, 2026 | 12.87B |
| June 29, 2026 | 13.16B |
| June 26, 2026 | 13.29B |
| June 25, 2026 | 12.90B |
| June 24, 2026 | 12.81B |
| June 23, 2026 | 12.42B |
| June 22, 2026 | 12.42B |
| June 18, 2026 | 12.56B |
| June 17, 2026 | 12.70B |
| June 16, 2026 | 12.61B |
| June 15, 2026 | 12.84B |
| June 12, 2026 | 12.87B |
| June 11, 2026 | 12.97B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Emergent BioSolutions, Inc. | 707.90M |
| Madrigal Pharmaceuticals, Inc. | 11.44B |
| United Therapeutics Corp. | 19.24B |
| AbbVie, Inc. | 532.50B |
| Tonix Pharmaceuticals Holding Corp. | 35.78M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 212.05M |
| Revenue (Quarterly) | 628.69M |
| Total Expenses (Quarterly) | 416.64M |
| EPS Diluted (Quarterly) | 0.8166 |
| Gross Profit Margin (Quarterly) | 96.71% |
| Profit Margin (Quarterly) | 33.73% |
| Earnings Yield | 5.83% |
| Operating Earnings Yield | 6.72% |
| Normalized Earnings Yield | 5.929 |